Methicillin Resistant Staphylococcus aureus (MRSA)

MRSA is mediated by the mecA gene; which is chromosomally coded. It alters penicillin-binding protein (PBP) present on S. aureus cell membrane to PBP-2a:

  • PBP is an essential protein needed for the cell wall synthesis of bacteria. β lactam drugs bind and inhibit this protein, thereby inhibiting cell wall synthesis.
  • The altered PBP2a of MRSA strains has less affinity for β lactam antibiotics; hence MRSA strains are resistant to all β lactam antibiotics.
  • BORSA strains (Borderline Oxacillin resistant S. aureus): Occasionally a non-mecA gene-mediated low-level resistance to oxacillin is observed in some strains of S.aureus, which is due to hyperproduction of β lactamase.
  • There is an increasing trend in the MRSA rates over the last few decades. Though it varies from place to place, overall about 30–40% of strains of S. aureus are MRSA.
  • MRSA rate in India is 30-40%. It is lowest in Scandinavian countries.

Methicillin Resistant Staphylococcus aureus (MRSA)

Types of MRSA

MRSA are either community or hospital-associated.

Community-associated MRSA (CA-MRSA)

  • It is mediated by the mecA gene subtype IV, V, VI.
  • They are usually more virulent and express several toxins such as PV toxin.
  • They cause invasive skin and soft tissue infections such as necrotizing fasciitis.

Hospital associated MRSA (HA-MRSA)

  • It is mediated by the mecA gene subtype I, II, III.
  • They are multidrug-resistant (but their virulence is low).
  • They cause perioperative wound infections in hospitals and nosocomial outbreaks (hospital staff are the major carries).

Note: CA-MRSA and HA-MRSA terminologies are becoming artificial nowadays; as many CA-MRSA strains have been isolated in hospitals and vice versa.

Detection of MRSA

  • Antimicrobial susceptibility test: Disk diffusion test can be done by using cefoxitin or oxacillin disks.
    • Cefoxitin is the recommended disk to be used.
    • If an oxacillin disk is used, then certain conditions to be maintained such as—using media containing 2–4% NaCl, incubation at 30 °C for 24 hours.
  • Oxacillin screen agar: Adding oxacillin 6 μg/ml and NaCl (2–4%) to the medium.
  • PCR detecting mecA gene.
  • Latex agglutination test detecting PBP-2a

Treatment of MRSA

  • Vancomycin is the drug of choice for MRSA.
  • Alternate drugs include:
    • Teicoplanin, linezolid, quinupristin-dalfopristin, tigecycline, oritavancin.
    • Daptomycin (for endocarditis and complicated skin infections),
    • Mupirocin 2% ointment (for nasal carriers of MRSA).
  • However, even simple orally effective drugs such as tetracycline, erythromycin, or cotrimoxazole may also be effective. These can be indicated in non-serious conditions, caused by CA-MRSA strains if found to be susceptible based on antimicrobial susceptibility report.
  • All β lactam drugs should be avoided. However, 5th generation cephalosporins, such as Ceftobiprole, ceftaroline, ceftolozane have shown some activity against MRSA.

References

  1. Apurba Sankar Sastry and Sandhya Bhat K (2018). Review of Microbiology and Immunology. Sixth Edition. Jaypee Brothers Medical Publishers (P) Ltd. ISBN: 978-93-86322-39-5.

About Author

Photo of author

Sagar Aryal, PhD

Dr. Sagar Aryal is a microbiologist, researcher, and science communicator from Nepal. He is also co-founder and Research Head of the Department of Natural Products at the Kathmandu Research Institute for Biological Sciences (KRIBS), where he leads research on natural product discovery and microbial biodiversity. Dr. Aryal earned his Ph.D. in Microbiology from Tribhuvan University, Kathmandu, Nepal, in 2025, supported by a DAAD Research Grant and a University Grants Commission (UGC) Nepal Ph.D. Fellowship. His research interests include Actinomycetes, Myxobacteria, microbial taxonomy, and natural products, particularly the discovery of bioactive compounds with potential pharmaceutical applications. He isolated and identified Nocardia nepalensis, a novel bacterial species from Nepal, contributing to understanding microbial diversity in the region. Dr. Aryal has published more than 16 research articles in international journals and contributed three book chapters to established academic publications. He has presented scientific research findings and developed international research collaborations through visits to more than 18 countries across Asia, Europe, North America, and Oceania. From 2023 to 2025, he served as the American Society for Microbiology (ASM) Young Ambassador to Nepal. Since December 2025, he has served as an Editorial Board Member of Scientific Reports, a Nature Portfolio journal. In recognition of his scientific contributions, Dr. Aryal received the NAST Science and Technology Youth Award 2025 from the Nepal Academy of Science and Technology. He previously received the Frs. Locke and Stiller Research Award (LSRA) for the 2017-2018 cycle from St. Xavier's College, Kathmandu, and a Nepal Academy of Science and Technology (NAST) Research Grant for 2017-2018. Alongside his scientific career, Dr. Aryal has more than 15 years of experience in blogging, content writing, and search engine optimization (SEO).